A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi

Background. Human-Immunodeficiency-Virus- (HIV-) related Kaposi's sarcoma (KS) has a high prevalence in Africa; however, there is minimal published data on treatment and outcomes in this population. Objective and Design. This was a prospective study of 50 patients, aiming to assess the impact o...

Full description

Saved in:
Bibliographic Details
Main Authors: H. Francis, M. J. Bates, L. Kalilani
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:AIDS Research and Treatment
Online Access:http://dx.doi.org/10.1155/2012/312564
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561099871879168
author H. Francis
M. J. Bates
L. Kalilani
author_facet H. Francis
M. J. Bates
L. Kalilani
author_sort H. Francis
collection DOAJ
description Background. Human-Immunodeficiency-Virus- (HIV-) related Kaposi's sarcoma (KS) has a high prevalence in Africa; however, there is minimal published data on treatment and outcomes in this population. Objective and Design. This was a prospective study of 50 patients, aiming to assess the impact of vincristine therapy on tumour response and survival and to assess palliative care outcomes in patients with HIV-related KS. Methods. 50 consecutive patients were recruited during 2008. Vincristine therapy and highly active antiretroviral therapy (HAART) were given. Tumour response, survival, and chemotherapy-related toxicities were documented. Palliative care outcomes were assessed using the African Palliative Care Association (APCA) Palliative Outcome Scale (POS). Results. The majority of patients were male, and the median age was 33 years. At baseline assessment, the median CD4 T-cell count was 263, and 50% patients had evidence of peripheral neuropathy. The overall response rate was 64% at 6 weeks, and median progression-free survival was 30 weeks. Treatment was generally well tolerated, with peripheral neuropathy the main dose-limiting toxicity. Conclusion. The combination of vincristine and HAART is feasible and effective in a low resource setting, although peripheral neuropathy is a dose-limiting factor. This patient group carries a high mortality and as such adequate access to palliative care is crucial.
format Article
id doaj-art-8a91cbbd5bb740689b66d9172af9a2fb
institution Kabale University
issn 2090-1240
2090-1259
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series AIDS Research and Treatment
spelling doaj-art-8a91cbbd5bb740689b66d9172af9a2fb2025-02-03T01:25:57ZengWileyAIDS Research and Treatment2090-12402090-12592012-01-01201210.1155/2012/312564312564A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, MalawiH. Francis0M. J. Bates1L. Kalilani2Department of Internal Medical Services, Ballarat Health Services, Ballarat, VIC 3350, AustraliaTiyanjane Clinic, Queen Elizabeth Central Hospital, C/- University of Malawi College of Medicine, Private Bag 360, Chichiri, Blantyre 3, MalawiUniversity of Malawi, College of Medicine, Private Bag 360, Chichiri, Blantyre 3, MalawiBackground. Human-Immunodeficiency-Virus- (HIV-) related Kaposi's sarcoma (KS) has a high prevalence in Africa; however, there is minimal published data on treatment and outcomes in this population. Objective and Design. This was a prospective study of 50 patients, aiming to assess the impact of vincristine therapy on tumour response and survival and to assess palliative care outcomes in patients with HIV-related KS. Methods. 50 consecutive patients were recruited during 2008. Vincristine therapy and highly active antiretroviral therapy (HAART) were given. Tumour response, survival, and chemotherapy-related toxicities were documented. Palliative care outcomes were assessed using the African Palliative Care Association (APCA) Palliative Outcome Scale (POS). Results. The majority of patients were male, and the median age was 33 years. At baseline assessment, the median CD4 T-cell count was 263, and 50% patients had evidence of peripheral neuropathy. The overall response rate was 64% at 6 weeks, and median progression-free survival was 30 weeks. Treatment was generally well tolerated, with peripheral neuropathy the main dose-limiting toxicity. Conclusion. The combination of vincristine and HAART is feasible and effective in a low resource setting, although peripheral neuropathy is a dose-limiting factor. This patient group carries a high mortality and as such adequate access to palliative care is crucial.http://dx.doi.org/10.1155/2012/312564
spellingShingle H. Francis
M. J. Bates
L. Kalilani
A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
AIDS Research and Treatment
title A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
title_full A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
title_fullStr A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
title_full_unstemmed A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
title_short A Prospective Study Assessing Tumour Response, Survival, and Palliative Care Outcomes in Patients with HIV-Related Kaposi's Sarcoma at Queen Elizabeth Central Hospital, Blantyre, Malawi
title_sort prospective study assessing tumour response survival and palliative care outcomes in patients with hiv related kaposi s sarcoma at queen elizabeth central hospital blantyre malawi
url http://dx.doi.org/10.1155/2012/312564
work_keys_str_mv AT hfrancis aprospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi
AT mjbates aprospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi
AT lkalilani aprospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi
AT hfrancis prospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi
AT mjbates prospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi
AT lkalilani prospectivestudyassessingtumourresponsesurvivalandpalliativecareoutcomesinpatientswithhivrelatedkaposissarcomaatqueenelizabethcentralhospitalblantyremalawi